Why Telehealth Brands Are Switching to Branded GLP-1s in 2026

What changed, in plain terms

The pivot has two dated causes, and neither says compounding is unsafe.

First, the federal shortages that opened the door to mass compounding ended. The FDA recorded the tirzepatide shortage as resolved in December 2024 and the semaglutide shortage as resolved in February 2025. (FDA, 2024 to 2025) Once a drug is off the shortage list, the broad legal basis for compounding large volumes of copies narrows sharply. That is a rule about supply, not about whether a given patient benefits.

Second, the legal landscape tightened. In March 2026 one large telehealth brand reached a settlement with Novo Nordisk and stepped back from advertised compounded semaglutide, keeping compounded options only for documented clinical need. (Hims investor relations, Mar 2026) Other brands read the same signals and adjusted. None of this is a clinical claim. It is companies responding to settlements and shifting rules.

Branded and compounded are not the same thing, and that is the point

A branded GLP-1 is an FDA-approved product made by its manufacturer. A compounded GLP-1 is something different: a preparation made by a state-licensed 503A pharmacy for one specific patient, under a prescription written for that person. It is a distinct compounded preparation. It is not a generic of the brand, and it is not equivalent to the branded product. Treating those as the same thing is exactly the framing regulators have pushed back on.

That distinction is why the pivot to branded does not erase compounding. The two things answer different questions. Branded GLP-1s are now more available and, in some cases, more affordable than they were a year ago. (NPR, May 2026) For other patients, a physician may decide that a patient-specific compounded preparation is the right clinical fit. Both can be legitimate. The decision belongs to a licensed clinician who knows your history, not to a headline.

Where 503A compounding still fits

There is a separate FDA action people often blur into this one. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B "bulks" list used by large outsourcing facilities, with public comment open through June 29, 2026. (FDA, Apr 2026; STAT, Apr 2026) That proposal targets 503B bulk compounding. It does not remove 503A patient-specific compounding, which stays available when a clinician documents a genuine clinical need, such as an allergy to a component or a dosing form a patient cannot use.

So the honest summary is this. The era of broadly advertising compounded copies is closing. Careful, prescription-based, patient-specific compounding is not.

The standard worth demanding from any provider, branded or compounded, is plain language. A good provider tells you whether your medication is branded or a 503A patient-specific preparation, names the licensed pharmacy, explains why that choice fits your situation, and never blurs the two to make a sale. If a brand will not say plainly which one you are getting, that tells you something. (This clarity is the standard sipra was built around.)

The bottom line for you

If your provider moved you from a compounded option to a branded one, it most likely reflects the 2024 to 2025 shortage resolutions and the 2026 legal climate, not a new finding that compounding harms patients. If a clinician keeps a patient-specific compounded preparation in the mix for a documented reason, that can be a legitimate, lawful choice too.

Your next step is simple. Ask your provider one question: is my GLP-1 branded or a 503A patient-specific preparation, and why is that the right fit for me? A provider who answers clearly is doing it right.